TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Up 1.4 %

Shares of TXMD stock opened at $2.14 on Friday. The business’s fifty day moving average is $2.08 and its 200 day moving average is $2.26. TherapeuticsMD has a twelve month low of $1.84 and a twelve month high of $4.50.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.31 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD at the end of the most recent quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.